Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients.

MLA

Riker, Adam I., et al. “Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients.” Ochsner Journal, vol. 14, no. 2, Summer 2014, pp. 164–74. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=103077959&authtype=sso&custid=ns315887.

APA

Riker, A. I., Rossi, G. R., Masih, P., Alsfeld, L. C., Denham, F., Tennant, L., Ramsey, W. J., Vahanian, N. N., & Link, C. J. (2014). Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients. Ochsner Journal, 14(2), 164–174.

Chicago

Riker, Adam I., Gabriela R. Rossi, Prerna Masih, L. C. Alsfeld, Fiona Denham, Lucinda Tennant, W. Jay Ramsey, Nicholas N. Vahanian, and Charles J. Link. 2014. “Combination Immunotherapy for High-Risk Resected and Metastatic Melanoma Patients.” Ochsner Journal 14 (2): 164–74. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=103077959&authtype=sso&custid=ns315887.